Abstract: A hydrophilic or lipophilic drug is entrapped or microencapsulated in a polyhydroxyalkanoate homopolymer or copolymer. The homopolymer or copolymer is synthesized in an aqueous medium containing a dissolved hydrophilic drug by in vitro enzyme polymerization of a hydroxyalkanoate Coenzyme A monomer to form microporous granules entrapping the drug. The enzyme may be a polyhydroxyalkanoate synthase, and the monomer may be 3-hydroxybutyryl Coenzyme A or 3-hydroxyvalerate Coenzyme A. The monomer is produced by reaction of a carboxylic acid group of a hydroxyalkanoic acid with a thiol group of Coenzyme A. To microencapsulate a lipophilic drug, droplets of oil containing a lipophilic drug are formed dispersed in an aqueous medium such as in the form of an oil-in-water emulsion. The polyhydroxyalkanoate homopolymer or copolymer is formed in the aqueous medium by the enzyme polymerization to form microcapsules having a core of oil containing the drug. The granules or microcapsules containing the drug may be dried.

Abstract: Differentially expressed Leishmania genes and proteins are described. One differentially expressed gene (A2) is expressed at significantly elevated levels (more than about 10 fold higher) in the amastigote stage of the life cycle when the Leishmania organism is present in macrophages than in the free promastigote stage. The A2 gene encodes a 22 kD protein (A2 protein) that is recognized by kala-azar convalescent serum and has amino acid sequence homology with an S-antigen of Plasmodium falcilparum Vietnamese isolate VI. Differentially expressed Leishmania genes and proteins have utility as vaccines, diagnostic reagents, as tools for the generation of immunological reagents and the generation of attenuated variants of Leishmania.

Abstract: A biosensor apparatus for detecting a binding event between a ligand and receptor. The apparatus includes an electrode substrate coated with a high-dielectric hydrocarbon-chain monolayer, and having ligands attached to the exposed monolayer surface. Binding of a receptor to the monolayer-bound ligand, and the resultant perturbation of the monolayer structure, causes ion-mediated electron flow across the monolayer. In one embodiment, the monolayers have a coil-coil heterodimer embedded therein, one subunit of which is attached to the substrate, and the second of which carries the ligand at the monolayer surface.

Abstract: A mechanism for orienting an end member utilizes paired five-bar linkages wherein two joints on each five-bar linkage may be actuated. Preferably the actuators are mounted at the base-link of the five bar linkages, such base-links being collinearly aligned. Two or three rotational and one translational degrees of freedom are available. This mechanism in its three or two degrees of rotational freedom variants has exceptional motion range, free of singularities, superior structural properties, and is easy to manufacture. This orienting mechanism can be mounted as an end member on a positioning mechanism having four main links herein three joints are actuated. The diagonally oppose joints of the positioning mechanism are respectively spherical and revolute. This positioning mechanism can operate with two actuators that are grounded and one that is elevated.

Abstract: This invention describes methods for increasing the toxicity of a cytostatic hydrophobic chemotherapeutic agent against resistant tumor cells in mammals which comprise administering a multidrug resistant reversing agent to the mammal in connection with the administration of the cytostatic hydrophobic chemotherapeutic agent in an amount effective to increase the toxicity of the chemotherapeutic agent, wherein the multidrug resistant reversing agent is a macrocyclic lactone compound. Examples of the macrocyclic lactone compounds useful in the present invention include, but are not limited to, the LL-F28249.alpha.-.lambda. series of compounds, the 23-oxo or 23-imino derivative thereof, the avermectins, the 22,23-dihydro derivatives thereof and the milbemycins. Compositions comprising the macrocyclic lactone compounds and the chemotherapeutic agents are also described herein.

Abstract: The present invention relates to materials and methods for identifying animals that are resistant or susceptible to diseases associated with intracellular parasites such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. More particularly, the present invention relates to the identification of a gene, called NRAMP1, which is associated with the susceptibility or resistance of an animal, such as an artiodactyla to diseases such as brucellosis, tuberculosis, paratuberculosis and salmonellosis. Still more particularly, the present invention relates to the identification of specific sequences of bovine NRAMP1 which associate with resistance or susceptibility to ruminant brucellosis, tuberculosis, paratuberculosis and salmonellosis, and to the method of identifying said sequences to identify animals who are susceptible or resistant to disease.

Abstract: Method for screening for a non-hormone agent potentially useful to treat a hormone disorder The method involves contacting a potential agent with a system containing a cellular component and a translation factor. The component and factor interact with one another in an intact normal cell in a manner responsive to the hormone to cause a modulation of translation in the cell. The method involves determining whether the agent causes a modulation of translation by the component and the factor analogous to that which occurs in intact cells in response to the hormone.

Abstract: A biosensor apparatus for detecting a binding event between a ligand and receptor. The apparatus includes an electrode substrate coated with a high-dielectric hydrocarbon-chain monolayer, and having ligands attached to the exposed monolayer surface. Binding of a receptor to the monolayer-bound ligand, and the resultant perturbation of the monolayer structure, causes ion-mediated electron flow across the monolayer. In one embodiment, the monolayers have a coil-coil heterodimer embedded therein, one subunit of which is attached to the substrate, and the second of which carries the ligand at the monolayer surface.

Abstract: The present invention relates to the diagnosis of severe diseases based on the determination of the presence of AGE-IgG autoantibodies in patients and to a method of treatment thereof. More precisely, the invention relates to a method for the diagnosis of severe diseases in patients, which comprises the steps of: a) incubating a solid support coated with an AGE antibody with a biological sample from said patient for a time sufficient for an immunoreaction to occur; and b) determining the presence of AGE-IgG autoantibodies present in said sample; whereby the presence of AGE-IgG autoantibodies in said patient's sample is indicative of a severe disease. Such severe diseases which may be diagnosed in accordance with the present invention include Rheumatoid arthritis, atherosclerosis, amyloidosis, diabetes, Henoch Schonlein Purpura, Crohn's disease and Coeliac disease.

Abstract: The present invention relates to novel human Prt1 (hPrt1) and eIF4G-like (p97) proteins which are involved in eukaryotic transcription. In particular, isolated nucleic acid molecules are provided encoding the human hPrt1 and p97 proteins. hPrt1 and p97 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of hPrt1 and p97 activity. Also provided are therapeutic methods for treating disease states associated with the hPrt1 and p97 proteins.

Abstract: For segmenting a sampled signal having at least two temporally separate interleaved dominant components for the purposes of extracting one or more of the separate components, an automated method of analyzing the sampled signal is used. By selecting a model for the signal and a processing window dimension, a variance between the signal and a model value for the signal is measured within the window over the sampled domain to obtain a noise indicator value. A corner geometry value for the sampled signal is calculated within the same window over the domain. A transition indicator value is generated based on a ratio of the corner geometry value and the model value. The segmentation points are identified based on the transition indicator value and at least one of the noise indicator value and the model value within the window over the domain.

Abstract: A mechanical ventilator for ventilating a patient employs an air displacement member mounted for oscillating motion in a chamber; preferably the chamber is semi-cylindrical and the air displacement member is a vane mounted for oscillating movement about an axis of rotation such that a free outer edge surface of the vane is maintained in closely spaced apart relationship with the interior wall of the chamber throughout the oscillating; the ventilator permits significant variation in the ventilation flow waveform.

Abstract: Disclosed is a method for inducing desorption of hydrogen for a metal hydride by applying thereto sufficient energy to induce hydrogen desorption by endothermic reaction. The energy that is so-applied is non-thermal and selected from the group consisting of mechanical energy, ultrasonic energy, microwave energy, electric energy, chemical energy and radiation energy.

Abstract: The surprising ability of the polysilicate microgels commonly known as "activated silica" to adsorb and to release heavy metals selectively as a function of pH is used in a novel method for separating metals from dilute aqueous solution by means of selective precipitation with and recovery from an activated silica absorbent, selected changes to the pH. The process is particularly intended for the economic purification of contaminated waste streams to recover valuable but toxic heavy metals from such effluents at a lower cost than hitherto possible, using an activated silica substrate which may be regenerated by alkali treatment.

Abstract: The present invention relates to the use of molecules capable of specifically binding a urokinase plasminogen activator receptor (uPAR) as diagnostic reagents for the detection of metastases in vivo. Such metastases can include, but are not limited to, micrometastases.

Abstract: The present invention relates to a cDNA probe for human methylenetetrahydrofolate reductase (MTHFR), and its uses. The probe of the present invention may be used for the identification of sequence abnormalities in patients with severe or mild MTHFR deficiency, including cardiovascular patients and patients with neurologic symptoms. A human MTHFR protein which hybridizes to the probe of the present invention may be used for therapy of MTHFR-deficiency patients by biochemical or pharmacological approaches.

Abstract: The variation in flow resistance of the respiratory system (Rrs) is determined as an indicator of variations in airway calibre, by oscillating the system, for example at 6 Hz for 5-15 minutes and determining the variations in ratio of the pressure difference (Prs) across the system that is in phase with flow, to flow V. The variation in airway calibre may be employed as a prognostic indicator in asthmatics and also to assess the efficacy of treatment.

Abstract: A postmitotic neuron containing an adenovirus vector, the neuron having been infected with the adenovirus vector at a multiplicity of infection of approximately 10 to approximately 50, and expressing a gene product encoded by a DNA molecule contained within said vector.

Abstract: The process for fabricating a ridge waveguide on a substrate uses a photosensitive sol-gel glass material prepared, according to a first embodiment, by mixing methacryloxypropyltrimethoxysilane (H.sub.2 C.dbd.C(CH.sub.3)CO.sub.2 (CH.sub.2).sub.3 Si(OCH.sub.3).sub.3) and methacrylic acid (H.sub.2 C.dbd.C(CH.sub.3)COOH) or, according to a second embodiment, by mixing methacryloxypropyltrimethoxysilane (H.sub.2 C.dbd.C(CH.sub.3)CO.sub.2 (CH.sub.2).sub.3 Si(OCH.sub.3).sub.3) with bis(s-butoxy)aluminoxytriethoxysilane. A thick film of photosensitive sol-gel glass material is first dip coated on at least a portion of the substrate. A photomask is applied to the film of photosensitive sol-gel glass material, and this sol-gel material is exposed to ultraviolet radiation through the opening(s) of the photomask to render a portion of the film insoluble to a given solvent and thereby imprint the ridge waveguide in that film.

Abstract: The invention encompasses tumorigenicity-inhibiting antisense oligonucleotide sequences complementary to mRNA or double-stranded DNA that encodes mammalian DNA methyl transferase. It further encompasses methods for inhibiting tumorigenicity and pharmaceutical composition comprising the tumorigenicity-inhibiting antisense nucleotide.